Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia
Immunotherapy · 2023
DOI: 10.2217/imt-2023-0140 ↗Kurz gefasst
Fallbericht in der Zeitschrift Immunotherapy, 2023. Verfasst von Syed B Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology & Allergy, Flinders Medical Centre, Bedford Park, Australia. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Thrombocytopenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Haemophagocytic lymphohistiocytosis (HLH) is a rare complication of immune checkpoint inhibitor therapy. A 55-year-old male with stable chronic lymphocytic leukemia presented with fevers and symptomatic anaemia after nine cycles of nivolumab for metastatic melanoma. Investigations were consistent with autoimmune haemolytic anemia and corticosteroids were initiated. Thrombocytopenia and elevated liver enzymes without evidence of chronic lymphocytic leukaemia transformation was present. Ferritin was elevated, and thus HLH was considered and subsequently confirmed on a bone marrow biopsy. Corticosteroid monotherapy was continued, with resolution of fevers and improvement in cytopenias and liver enzymes. A six month corticosteroid tapering regimen was initiated, and he remains in HLH remission. This case highlights the importance of prompt recognition of immune checkpoint inhibitor-related HLH in patients with concurrent haematological malignancy. A 55-year-old man had skin cancer and treatment was started. He also had a blood cancer around the same time that was not causing any problems. The skin cancer treatment started to cause problems many weeks later. His immune system started to react and become more active and so his liver started to suffer. The treatment for his skin cancer was stopped and steroids were started, which eventually improved his condition. These treatments for skin cancer can activate the immune system, but to this extent is not very common. It is important to know that it is possible and needs to be actioned early.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology & Allergy, Flinders Medical Centre, Bedford Park, Australia.
- School of Medicine & Public Health, Flinders University, Bedford Park, 5042, Australia.
- Department of Haematology, Flinders Medical Centre, Bedford Park, 5042, Australia.
- Department of Oncology, Flinders Medical Centre, Bedford Park, 5042, Australia.
ORCID-Profile: Syed B Ali
Zitieren
APA
Ali, S. B., Kuss, B., Karapetis, C., Hughes, T., & Smith, A. (2023). Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia. Immunotherapy. https://doi.org/10.2217/imt-2023-0140
Vancouver
Ali SB, Kuss B, Karapetis C, Hughes T, Smith A. Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia. Immunotherapy. 2023. doi:10.2217/imt-2023-0140
BibTeX
@article{Ali2023,
author = {Ali, Syed B and Kuss, Bryone and Karapetis, Chris and Hughes, Tiffany and Smith, Anthony},
title = {Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2023-0140}
}
EUVIMED